지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.5
- 수록면
- 217 - 234 (18page)
- DOI
- 10.4168/aair.2024.16.3.217
이용수
초록· 키워드
오류제보하기
Concerns regarding the safety of beta-2 agonists have led to revisions of the major asthma guidelines to better address these issues. Although these updates allow for a combination of previous and current strategies, they may confuse clinical practitioners. Beta-2 agonists are vital for alleviating asthma symptoms by relaxing smooth muscles; however, they also pose significant risks by inducing pro-inflammatory mediators both in vitro and in vivo. In addition to the risks of overuse and symptom masking, the use of beta-agonists alone at therapeutic doses can worsen airway inflammation and enhance virus-induced inflammation during asthma exacerbation. Inhaled corticosteroids (ICS) can effectively prevent these adverse effects. With new insights into the mechanisms of these adverse events, reserving short-acting beta-agonists for acute symptom relief during exacerbations and only for those who are already on ICS or oral steroids represents a careful approach to using beta-agonists with least adverse effects in patients with asthma. However, a major drawback of this approach is the potential non-compliance with ICS, leading to beta-agonist use without the necessary counteraction by ICS. An optimal strategy, both during and outside exacerbations, would integrate beta-agonists into an anti-inflammatory regimen that includes ICS, ideally combined with the same inhaler to ensure their concurrent use where finances allow. This would maintain the beneficial effects of beta-agonists, such as bronchodilation, while preventing the adverse effects from the induction of inflammatory mediators. This method is aligned with diverse clinical settings, maximizes the safe use of beta-agonists, and supports a comprehensive guideline-compliant management strategy.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
Tuberculosis and Respiratory Diseases
2018 .01
-
Safety and efficacy of beta-3 adrenergic agonists in treating neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis
Investigative and Clinical Urology
2024 .05
-
Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review
International Neurourology Journal
2021 .09
-
Combination of a Rapidly Penetrating Agonist and a Slowly Penetrating Antagonist Affords Agonist Action of Limited Duration at the Cellular Level
Biomolecules & Therapeutics(구 응용약물학회지)
2019 .01
-
Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study
Allergy, Asthma & Immunology Research
2021 .11
-
Effects of Asthma Medication Type on Asthma Exacerbation in a Real-World Setting
Yonsei Medical Journal
2022 .07
-
Airway foreign body occurs unintentionally during anesthetic management of patient with asthma
의생명과학
2019 .01
-
Dilemma of Asthma Treatment in Mild Patients
Tuberculosis and Respiratory Diseases
2019 .01
-
Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2024 .04
-
Beta-amyloid imaging in dementia
영남의대학술지
2018 .01
-
천식 치료의 원칙과 새로운 약제의 적절한 사용
대한의사협회지
2022 .01
-
Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
Allergy, Asthma & Immunology Research
2017 .01
-
Risk, Mechanisms and Implications of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) among Individuals With Asthma: a Systematic Review and a Case Study
Allergy, Asthma & Immunology Research
2021 .09
-
정밀한 천식 치료를 위한 생물학적 제제
Allergy Asthma & Respiratory Diseases
2019 .01
-
The effects of Dopamine D1 agonist on the survival of human mesenchymal stem cells
한국실험동물학회 학술발표대회 논문집
2020 .02
-
중증천식의 치료
대한내과학회지
2018 .01
-
Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
Journal of Breast Cancer
2015 .01
-
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology and Metabolism
2021 .01
-
A Clinician’s Perspective on the Mechanism of β3-Adrenoceptor Agonists in the Bladder
International Neurourology Journal
2017 .01
최근 본 자료
댓글(0)
0